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Abstract
Background: Tumor necrosis factor (TNF) has pleiotropic functions during both the demyelinating autoimmune
disease multiple sclerosis (MS) and its murine model experimental autoimmune encephalomyelitis (EAE). How TNF
regulates disability during progressive disease remains unresolved. Using a progressive EAE model characterized by
sustained TNF and increasing morbidity, this study evaluates the role of unregulated TNF in exacerbating central
nervous system (CNS) pathology and inflammation.
Methods: Progressive MS was mimicked by myelin oligodendrocyte glycoprotein (MOG) peptide immunization
of mice expressing a dominant negative IFN-γ receptor alpha chain under the human glial fibrillary acidic protein
promoter (GFAPγR1Δ). Diseased GFAPγR1Δ mice were treated with anti-TNF or control monoclonal antibody during
acute disease to monitor therapeutic effects on sustained disability, demyelination, CNS inflammation, and blood
brain barrier (BBB) permeability.
Results: TNF was specifically sustained in infiltrating macrophages. Anti-TNF treatment decreased established
clinical disability and mortality rate within 7 days. Control of disease progression was associated with a
decline in myelin loss and leukocyte infiltration, as well as macrophage activation. In addition to mitigating
CNS inflammation, TNF neutralization restored BBB integrity and enhanced CNS anti-inflammatory responses.
Conclusions: Sustained TNF production by infiltrating macrophages associated with progressive EAE exacerbates
disease severity by promoting inflammation and disruption of BBB integrity, thereby counteracting establishment of
an anti-inflammatory environment required for disease remission.
Keywords: Progressive multiple sclerosis, Experimental autoimmune encephalomyelitis, Astrocytes, Interferon γ,
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Background
Tumor necrosis factor (TNF) is a pleiotropic cytokine
that regulates numerous physiological and pathological
processes. Specifically, the pathophysiology of a variety
of neurological disorders, including the demyelinating
autoimmune disease multiple sclerosis (MS) is associated
with TNF [1]. Expression of TNF in active MS lesions
[2], as well as elevated TNF in serum and cerebral spinal
fluid, correlates with lesion activity [3]. Increased TNF
in the central nervous system (CNS) of animals undergo-
ing experimental autoimmune encephalomyelitis (EAE), a
rodent model of MS, supports pro-inflammatory and dis-
ease enhancing activity. Interestingly, increased TNF in
spinal cords also coincides with neuropathic pain in rats
undergoing EAE [4]. Furthermore, transgenic expression
of TNF within the CNS leads to demyelinating disease
[5–7]. This is consistent with the ability of TNF to both
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directly induce oligodendrocyte apoptosis [8–10] and
indirectly inflict excitotoxic damage to oligodendro-
cytes and neurons by modulating the release of glutam-
ate from astrocytes [8, 11]. A pro-inflammatory role of
TNF in CNS autoimmune disease is further supported
by the observations that TNF blockade prior to disease
onset prevents or ameliorates EAE [12, 13]. The com-
pelling evidence suggesting destructive roles for TNF in
MS patients, EAE, in vitro studies, and other auto-
immune diseases provided the basis to target TNF to
treat MS patients. Infliximab, a mouse/human chimeric
monoclonal anti-TNF antibody, was used in a first open-
label phase trial I on two rapidly progressing MS patients
[14]. Both patients showed increased lesion numbers,
leukocytes in cerebrospinal fluid, and IgG titers correl-
ating with an augmentation in disease activity. More-
over, a randomized Phase II placebo-controlled trial
with Lenercept, an extracellular domain of dimeric TNFR1
fused with IgG1 heavy chain fragment, was conducted in
relapsing-remitting MS patients. However, the trial was
abruptly terminated due to a dose-dependent increase in
frequency and severity of MS attacks [15].
EAE has provided insights into the dual pro- and anti-
inflammatory activities exhibited by TNF during CNS
autoimmunity. Two forms of TNF, a soluble and trans-
membrane form, interact with two distinct receptors,
namely TNF receptor 1 (TNFR1) and TNF receptor 2
(TNFR2), which differ in expression and ligand affinity.
The pleiotropic functions of TNF are predominantly
dictated by interaction with these two receptors. Soluble
TNF with higher affinity for TNFR1 mediates apoptosis
and chronic inflammation [16]. Conversely, transmem-
brane TNF with higher affinity for TNFR2 activates
genes important for cell survival, resolution of inflam-
mation, and even myelination [17–19]. Consistent with
these concepts, both TNF−/− and TNFR2−/− mice develop
more severe EAE [17, 20, 21], while TNFR1−/− mice are
protected from EAE [20]. The absence of both TNFR1
and TNFR2 delays disease onset but does not protect [20].
Furthermore, mice expressing only transmembrane TNF
demonstrated its protective role during EAE [17]. A
recent pharmacological approach eliminating only soluble
TNF without inhibiting transmembrane TNF supported
the concept that inhibition of soluble TNF is therapeutic
during EAE [22]. Interestingly, following inhibition of
soluble TNF, recovery from paralysis was more rapid and
associated with increased axonal preservation and remye-
lination [22]. Similar to the analysis of EAE in TNF−/−
mice [17, 20, 21], inhibition of both soluble TNF and
transmembrane TNF were not protective [13, 22, 23].
Collectively, these studies suggest that the protective
effects of TNF in EAE are mediated by the interaction of
transmembrane TNF with TNFR2 and that blocking
these anti-inflammatory properties during the relapsing-
remitting phase of MS contributes to the adverse out-
come. Contrasting these studies predominantly focusing
on the effect of TNF on either disease induction or the
acute phase of EAE, the study herein specifically ad-
dresses the role of TNF during a chronic, non-remitting
form of EAE. We have previously reported that mice, in
which astrocytes are unable to respond to interferon
gamma (IFN-γ), develop a chronic progressive form of
EAE [24] with many pathophysiological hallmarks of
progressive MS. Increasing clinical disease and mortality
in this model are associated with sustained inflammation,
sustained interleukin-6 (IL-6) secretion [25], increased
TNF [24], and increased myelin destruction [24, 25].
Blockade of IL-6, associated with a variety of neurological
dysfunctions [25–27], was therapeutic by reducing clinical
disease, inflammation, and demyelination [25]. Based on
the ability of TNF to induce IL-6 secretion by astrocytes
[28–30] and the reduction in secondary progressive dis-
ease in MS patients treated with a TNF inhibitor [31, 32],
we examined the therapeutic potential of inhibiting both
soluble and transmembrane TNF in the progressive EAE
model. Comparison of acute EAE in both wild-type (WT)
and GFAPγR1Δ mice confirmed that TNF is predomin-
antly produced by both macrophages and microglia.
However, while TNF levels decreased in both popula-
tions in WT mice during disease remission, TNF was
specifically sustained by infiltrating macrophages dur-
ing progressive EAE. Although blockade of TNF did
not promote remission in WT mice, it significantly
ameliorated clinical symptoms and decreased mortal-
ity during progressive EAE. Reduced clinical disease
following TNF blockade was associated with decreased
CNS macrophage and T cells accumulation, including
both Th1 and Th17 cells, as well as reduced microglial
and macrophage activation. Anti-TNF therapy further
restored blood brain barrier (BBB) integrity and promoted
an anti-inflammatory milieu consistent with diminished
tissue damage. Overall, the data support distinct regula-
tion of macrophages and microglia during progressive
disease, with sustained TNF production in macrophages
contributing to clinical disability and CNS inflammation.
Amelioration of progressive demyelinating encephalomy-
elitis by TNF blockade supports the concept that TNF
is a potential target for therapeutic approaches in both
primary and secondary progressive MS.
Methods
Mice
Homozygous H-2b GFAP/IFN-γR1ΔIC (GFAPγR1Δ) trans-
genic mice expressing a dominant negative IFN-γ receptor
alpha chain under control of the glial fibrillary acidic
protein (GFAP) promoter [24, 33] were bred locally.
C57BL/6 (H-2b) WT mice were purchased from the
National Cancer Institute (Frederick, MD). FVB/N-Tg
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(GFAP-GFP) 14Mes/J mice (The Jackson Laboratory,
Bar Harbor, ME) were backcrossed 11 times into the
C57BL/6 background to generate C57BL/6 WT mice
expressing green fluorescent protein (GFP) under the
GFAP promoter (GFAP-GFP). GFAP-GFP mice were
crossed with GFAPγR1Δ mice to generate dual transgenic
GFAP-GFP/GFAPγR1Δ mice. All animal experiments
were conducted in mice from both sexes in accordance
with the National Institute of Health Guide for the Care
and Use of Laboratory Animals. All procedures were
performed in compliance with protocols (Protocol num-
ber 1165) approved by the Cleveland Clinic Institutional
Animal Care and Use committee.
EAE
EAE was induced by immunizing mice with myelin
oligodendrocyte glycoprotein (MOG)35–55 peptide (Bio-
synthesis, Lewisville, TX) emulsified at 3 mg/ml in PBS
with an equal amount of incomplete Freund’s Adjuvant
(IFA; Sigma-Aldrich, St. Louis, MO) supplemented with
5 mg/ml of Mycobacterium tuberculosis, strain H37Ra
(Difco, Detroit, MI). Mice were immunized subcutane-
ously with 200 μl emulsion over the flanks. Mice also
received 200 ng of Pertussis toxin (Sigma-Aldrich) in
200 μl of PBS intraperitoneally (i.p.) on the day of the
initial immunization and at day 2 post-immunization
(p.i.). Mice received a second immunization with 200 μl
emulsion in the left side over the flanks 7 days later.
Animals were scored daily for clinical symptoms as
follows: 0 = no signs of disease, 1 = flaccid tail, 2 = flaccid
tail and partial hind limb paralysis, 3 = complete hind
limb paralysis, 4 =moribund state, 5 = dead.
Astrocyte and microglia purification by cell sorting
EAE was induced in GFAP-GFP/GFAPγR1Δ as described
above. At d19 and d30 p.i., brains were homogenized
using a Papain Neuronal Tissue Dissociation Kit (Miltenyi,
Auburn CA). Cells from homogenates were resuspended
in RPMI medium containing 25 mM HEPES (pH 7.2)
and adjusted to 30 % Percoll (Amersham Bioscience,
Piscataway, NJ). A 1-ml underlay of 70 % Percoll was
added prior to centrifugation at 800×g for 30 min at
4 °C to separate mononuclear cells from myelin deb-
ris. Cells from the 30/70 % interface were collected
and washed in RPMI medium. Antibody non-specific
binding was prevented with mouse anti-CD16/CD32
(2.4G2; BD Biosciences, San Diego, CA) and 10 % mixture
of normal goat, human, mouse, and rat serum for 10 min
on ice. To distinguish astrocytes from microglia and
inflammatory cells, recovered cells were stained with
anti-CD45 (clone 30-F11) APC and CD11b (M1/70)
PerCp (BD Biosciences, San Diego, CA). Astrocytes
were identified as GFAP-GFP+ CD45-, whereas microglia
were defined as CD45int CD11b+. Cells were purified by
FACS using a FACSAria (BD Biosciences) and FACS Diva
software (BD Biosciences).
Anti-TNF treatment
Mice received 0.5 mg of either neutralizing rat anti-
murine TNF (clone MD6-XT3.11) or control rat IgG1
anti-β-galactosidase (clone GL113) monoclonal antibody
(mAb) i.p. starting at the peak of acute disease (day 19
p.i.) followed by injections every 2 days for a total of four
dosages. Anti-TNF mAb was purchased from Bioxcell,
West Lebanon, NH. The GL-113 hybridoma, originally
obtained from Dr. Robert Coffman (DNAX Corp, Palo
Alto, CA) was adapted to BD cell Serum Free Medium
(BD, Bedford, MA). After propagation in a BD CELLine
device, the mAb concentration was determined by optical
density at 480 nm. All mAbs were diluted to 1 mg/ml in
endotoxin free PBS and stored at −20 °C until use.
Flow cytometry
Brains from mice perfused with ice-cold PBS were in-
dividually homogenized in 4 ml of RPMI medium
containing 25 mM HEPES, pH 7.2 using chilled Ten-
broeck tissue grinders. Homogenates were centrifuged
at 450×g for 7 min. Supernatants were collected and
immediately stored at −80 °C for cytokine analysis
(see below). Cells were resuspended in 30 % Percoll and
isolated by centrifugation (800×g for 30 min at 4 °C) onto
a 70 % Percoll cushion as described above for cell sorting.
Non-specific antibody binding was inhibited by incubation
with anti-CD16/CD32 (2.4G2 mAb) and a 10 % mixture
of normal goat, human, mouse, and rat serum for 15 min
on ice. CD45 (30-F11) APC, CD4 (GK1.5) PercP-Cy5.5,
CD8a (53−6.7) FITC, and CD11b (M1/70) PE mAbs (BD
Biosciences) were used to analyze microglia and infiltrat-
ing inflammatory cells (BD Biosciences). Microglia and
inflammatory cells were distinguished based on their
differential CD45 expression. Major histocompatibility
complex (MHC) class II (clone 2G9, BD Biosciences)
expression was determined as a measure of macro-
phage and microglial activation. To detect intracellu-
lar cytokines cells were stimulated ex vivo for a total
of 4 h at 37 °C with phorbol 12-myristate 13-acetate
(PMA) (10 ng/ml, Acros Organics, NJ) and ionomycin
(1 μM, Calbiochem, Spring Valley, CA). Monensin (2 μM,
Calbiochem) was added for the last 2 h of incubation.
Following permeabilization (Cytofix/Cytoperm Reagent,
BD Biosciences) intracellular cytokines were detected
using anti-IFN-γ (clone XMG1.2; BD Bioscience) and
anti-IL-17 (clone TC11-18H10; BD Bioscience) mAb. To
determine intracellular TNF, cells were incubated in
serum free RPMI at 37 °C for 4 h with Monensin (2 μM)
added for the last 2 h. After 4 h, cells were perme-
abilized with cytofix/cytoperm reagent (BD Biosciences)
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and stained using PE anti-TNF mAb (clone MP6-XT22;
BD, Bioscience).
ELISA and BBB permeability
IFN-γ and IL-17 were determined by ELISA as previ-
ously described [34] using mAb pairs and recombin-
ant cytokine standards from BD Bioscience. IL-10 was
measured by ELISA using reagents from eBiosciences,
San Diego, CA.
BBB integrity was determined by measuring perme-
ability to sodium fluorescein (NaF) as described [35].
Mice received 100 μl of 10 % NaF in PBS i.p. After
10 min, cardiac blood was collected, followed by trans-
cardial perfusion with ice-cold PBS. Brains and spinal
cords were harvested and snap-frozen in liquid nitrogen.
Each tissue was weighed and homogenized in 10 ml of
PBS per gram of tissue followed by centrifugation for
2 min at 14,000×g at 4 °C. Supernatants were mixed
with an equal volume of 15 % trichloroacetic acid
and centrifuged at 10,000×g for 10 min at 4 °C. After
centrifugation, 125 μl of 5 N NaOH was added to
500 μl of supernatant. NaF concentrations were deter-
mined by comparison to standards ranging from 125
to 4000 μg on a SpectraMax M2 at an excitation of
485 nm, emission of 530 nm, and gain of 50 (Molecular
Devices, Sunny Valley, CA). CNS values were normalized
to NaF serum levels as follows: (μg florescence tissue/mg
protein)/(μg fluorescence sera/μl of blood) [35]. Data are
presented as fold increase by comparing experimental
levels to those obtained from naïve WT mice with intact
BBB.
Immunohistochemistry and histopathology
Spinal cords from WT and GFAPγR1Δ mice perfused
with ice-cold PBS during acute and chronic EAE were
collected in OCT embedding compound (Scigen Scien-
tific, Gardena CA). Frozen sections were stained with
anti-mouse TNF (1:100) (Abcam Inc., Cambridge, MA),
anti-mouse Iba1 (1:200) (Wako Chemicals, Richmond,
VA) or anti-mouse GFAP (1:5000) (Dako, Carpinteria,
CA), and Prolong Gold for nuclear staining (Molecular
Probes, Eugene, OR) as previously shown [36]. Immuno-
reactivity was visualized with species-specific fluores-
cently labeled secondary antibodies (goat anti-rabbit
Alexa Fluor 488, Life Technologies Carlsbad, CA; goat
anti-mouse Alexa Fluor 594, Invitrogen, Grand Island,
NY). Images were captured using a multiphoton micro-
scope (Leica TCS SP5 II, Lawrenceville, GA). TNF+ area
was calculated as an average of three different fields per
group using Image-Pro.
Spinal cord frozen sections were also stained with
laminin (1:2000) (Abcam Inc., Cambridge, MA), IgG
conjugated with Alexa Fluor-594 (1:200) (Jackson La-
boratories, Sacramento CA), and Prolong Gold. Laminin
was visualized using goat anti-rabbit Alexa Fluor-488 (Life
Technologies).
Spinal cords were obtained from mice perfused with
ice-cold PBS and fixed in Zn Formalin. Each spinal cord
was dissected into six sections, two of each correspond-
ing to the cervical, thoracic, and lumbar regions and
embedded in paraffin. To determine the percentage
demyelination, 6-μm cross sections were stained with
Luxol Fast Blue (LFB), scanned at 40× and digitally
imaged at high resolution with an Aperio Scanscope
(Vista, CA) as described [25]. Aperio software was used
to quantify areas of demyelination within the white
matter tracks.
Gene expression analysis
Following PBS perfusion, snap-frozen spinal cords were
homogenized in Trizol (Invitrogen) using a TissueLyser
with stainless beads (Qiagen, Valencia, CA). RNA was
extracted according to the manufacturer’s instructions
followed by DNAse I (Ambion, Austin, TX) treatment
for 30 min at 37 °C. M-MLV Reverse Transcriptase (Invi-
trogen), oligo-dT primers (20 μM) (Promega, Madison,
WI), and random primers (20 μM) (Promega) were used
to synthesize cDNA. Gene expression analysis was per-
formed by quantitative real-time PCR using a 7500 Fast
real-time PCR system (Applied Biosystems, Foster City,
CA). Foxp3 and IL-27 p28 messenger RNA (mRNA) levels
were detected by Taqman Gene Expression Assay using
Taqman primers (Foxp3 -Mm00475162_m1, IL-27 p28-
Mm00461162_m1) (Life Technologies, Carlsbad, CA).
RNA was extracted from FACS-purified cell popula-
tions frozen in 400 μl of Trizol reagent (Invitrogen,
Waltham, MA). Removal of DNA contamination and
cDNA synthesis were performed as described above.
TNF mRNA expression analysis was determined using
4 μl of cDNA and SYBR Green master mix (Applied




Data represent the mean ± SEM. Significance was de-
termined using two-tailed Student’s t test or Mann-
Whitney Rank Sum test using SigmaStat v3.5. A value
of p < 0.05 was considered statistically significant. Graphs
were plotted using GraphPad Prism v5.02 software.
Results
TNF production is sustained in macrophages during
progressive EAE
In active MS lesions, TNF is produced by microglia,
macrophages, and astrocytes, but not T cells [2]. Simi-
larly, analysis of acute EAE in a relapsing/remitting
model indicated that TNF is primarily produced by
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microglia and/or bone marrow derived macrophages
with little or no expression by T cells [37]. Elevated TNF
mRNA expression in the CNS is also a feature distin-
guishing acute and progressive EAE in GFAPΔR1γ com-
pared to WT mice [33], although the primary source is
unknown. To first verify that TNF protein production in
the CNS reflects differences in mRNA, TNF expression
was monitored by histology in spinal cords of WT and
GFAPΔR1γ mice (Fig. 1a). Naïve mice did not express
detectable TNF (data not shown). In mice undergoing
acute EAE, TNF was readily detected in white matter of
both groups with an overall similar distribution and
focal clustering (Fig. 1a). Focal clustering of anti-TNF
reactivity was also present in gray matter, albeit less
intense (data not shown). TNF mRNA declines during
the recovery phase of EAE in WT mice [38, 39], which
is characterized by sustained demyelination with min-
imal active inflammation [39]. By contrast, increasing
morbidity during progressive EAE is associated with
sustained TNF mRNA expression [24]. This pattern was
also reflected by histological analysis. Contrasting the
minimal TNF production during the recovery phase in
WT mice, TNF was sustained in the CNS of mice with
progressive EAE, although at lower levels compared to
the acute phase (Fig. 1a). Irrespectively, the overall
punctate, constricted nature of TNF mAb reactivity
was similar between groups.
We next examined the cell types associated with TNF
production. As astrocytes can be a potential source of
TNF [2, 40, 41], we specifically assessed if IFN-γ regu-
lates TNF in astrocytes. Comparative analysis of TNF
mRNA in astrocytes and microglia purified from dual
transgenic GFAPΔR1γ/GFAP-GFP mice revealed prom-
inent TNF mRNA levels in microglia during both acute
and chronic EAE (Fig. 1b). By contrast, astrocytes showed
minimal TNF mRNA upregulation compared to naïve
mice. There was also no evidence of TNF co-localization
with either GFAP+ astrocytes or T cells by histology
Fig. 1 TNF is primarily produced by Iba1+ cells during EAE. a Confocal Z-stack images showing TNF in white matter of spinal cords from WT and
GFAPΔR1γ during acute and chronic EAE. Magnification ×100. Bar graph depicts TNF+ area calculated as an average of three fields per group.
b TNF mRNA expression in FACS sorted astrocytes and microglia from GFAP-GFP/GFAPΔR1γ during acute (d19 p.i.) and chronic EAE (d30 p.i.).
c Confocal Z-stack images (magnification ×100) with orthogonal views illustrating TNF co-staining with Iba1 in spinal cord white matter from WT
and GFAPΔR1γ during acute and chronic EAE. Data are representative of three mice per group. P values determined by Student’s t test
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during either the acute or chronic phase in either mouse
group (data not shown). TNF primarily co-localized with
Iba1+ cells in both groups of mice undergoing acute EAE
(Fig. 1c). The sparse CNS cells producing TNF during the
recovery phase in WT mice were also Iba1+ (Fig. 1c).
Similarly, although the numbers were higher during
progressive EAE, TNF was primarily associated with
Ibal+ cells. As the overlap between Iba1 and TNF stain-
ing was limited, side view images are shown in Fig. 1c
to confirm juxtaposition of TNF to Iba1+ membranes
and containment within Iba1+ cells. The punctate TNF
staining pattern was consistent with vesicle cytosolic
associated membrane TNF, rather than dispersed sur-
face associated TNF [42], implicating TNF was cleaved
once fused with the cell membrane. These results con-
firmed macrophages and/or microglia as prominent
sources of TNF, independent of IFN-γ signaling to as-
trocytes, and are consistent with data from the acute
phase in a relapsing/remitting model of EAE [37].
Flow cytometry was used to further distinguish between
Iba1+ CD45low microglia and CNS infiltrating CD45hi
CD11b+ macrophages as the predominant source of TNF.
The majority (~70 %) of microglia produced TNF during
acute EAE in both mouse groups, with only a minor
increase at the population level evident by mean fluores-
cent intensity (MFI) in GFAPΔR1γ mice (Fig. 2a). By
contrast, although only a third of CNS infiltrating macro-
phages produced TNF in either group, increased TNF
production per cell in macrophages from GFAPΔR1γ mice
was supported by increased MFI. During the remission
phase in WT mice, the proportion of cells producing TNF
dropped to less than 7 % for both macrophages and
microglia (Fig. 2b). Moreover, the MFI was extremely low
(Fig. 2b). Similarly, during progressive EAE, both the
proportion and MFI of microglia producing TNF were
reduced (Fig. 2b). By contrast, TNF secretion was main-
tained in ~40 % of macrophages with MFI at nearly the
levels expressed during the acute phase (Fig. 2b), distinct
from the paucity of TNF producing macrophages in re-
mitting WT mice. These data are consistent with mRNA
results suggesting minimal TNF production during the
chronic/repair phase of EAE in WT mice [38, 39]. More-
over, they provide the first evidence that TNF is down
regulated in both microglia and macrophages during
remission of EAE. By contrast, despite the ~50 % reduc-
tion in infiltrating macrophages during the progressive
phase relative to acute EAE [24], macrophages sustained
TNF expression in GFAPΔR1γ mice. The loss of microglia
but not macrophages secreting TNF, suggests differential
regulation of both populations in the same environment.
The progressive phase does therefore not merely reflect a
sustained acute phase.
TNF blockade limits disease progression and
demyelination during progressive EAE
To determine if sustained macrophage derived TNF
contributes to progressive EAE, GFAPγR1Δ and WT
mice undergoing acute disease were each divided into
Fig. 2 TNF secretion is sustained in infiltrating macrophages during progressive EAE. TNF production by macrophages and microglia determined
by intracellular staining during a acute (d19 p.i.) and b chronic (d30 p.i.) EAE in WT (black line) or GFAPΔR1γ (red line) mice. Numbers in histograms
depict the percentage of TNF producing WT cells (black) or GFAPΔR1γ cells (red). Dotted line represents isotype control. Bar graphs show mean
fluorescence intensity (MFI) of TNF staining in macrophages and microglia from WT and GFAPΔR1γ mice during acute and chronic disease.
Data represent the mean values and ± SEM of three independent experiments with six mice per group per experiment. P values determined by
Student’s t test
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two cohorts (Fig. 3a). The cohorts were treated with
either anti-TNF mAb neutralizing both soluble and
transmembrane TNF or an isotype control mAb. TNF
blockade in WT mice had little effect on clinical symp-
toms during EAE recovery (Fig. 3a), consistent with
previous data [13, 22, 23]. By contrast, TNF blockade
significantly improved clinical disease within 10 days in
GFAPγR1Δ mice (Fig. 3a). Direct comparison of clinical
scores to recovering WT mice already revealed dramatic
clinical improvement of GFAPγR1Δ mice within 6 days
after two anti-TNF treatments, while disease continued
to deteriorate in the control cohort (Fig. 3b). In
addition to limiting disease progression, TNF blockade
also significantly reduced mortality in GFAPγR1Δ mice
(Fig. 3c).
During progressive EAE, GFAPγR1Δ mice exhibit
increased demyelination compared to WT mice [24]. To
determine to what extent clinical improvement by TNF
blockade is associated with limited demyelination, we
evaluated demyelination in spinal cords of GFAPγR1Δ
mice treated with anti-TNF compared to GFAPγR1Δ
controls and WT mice. Anti-TNF treatment reduced
demyelination in the GFAPγR1Δ mice to approximately
the level found in WT mice (Fig. 3d). Quantitative
analysis of demyelination in white matter revealed that
~23 % of white matter area was affected in control
treated-GFAPγR1Δ mice compared to only ~8 % in WT
mice, consistent with previous data [24, 25]. TNF block-
ade reduced demyelination by 46 to ~12 % of white
matter area, approximating the extent of demyelination
in WT mice. Irrespective of the severe pathology prior
to treatment during acute EAE in GFAPγR1Δ mice,
clinical improvement thus correlated with limited de-
myelination similar to levels observed in untreated WT
mice (Fig. 3b).
TNF blockade limits inflammation indiscriminately during
progressive EAE
To determine if TNF also contributed to sustained CNS
immune cell infiltration during progressive EAE, CNS
inflammatory cells in anti-TNF treated GFAPγR1Δ were
compared to control treated and WT mice by flow
cytometry. TNF blockade in GFAPγR1Δ mice indeed
reduced inflammatory cells to approximately the level in
WT mice with resolving EAE (Fig. 4a). However, similar
frequencies of CD4+ T cells, CD8+ T cells, and macro-
phages within the inflammatory population (Fig. 4b)
suggested a global anti-inflammatory effect, rather than
Fig. 3 Anti-TNF treatment ameliorates progressive EAE. EAE was induced in WT and GFAPΔR1γ mice. At the peak of acute disease (d19 p.i.),
WT and GFAPΔR1γ were divided into two groups with equal clinical scores. WT + αTNF and GFAPΔR1γ + αTNF received i.p. injections of anti-TNF
mAb (0.5 mg), whereas WT and GFAPΔR1γ received equal amounts of isotype mAb control. Mice were treated every 2 days for a total of four
dosages. a Clinical scores of αTNF treated and control cohorts pre and 10 days post treatment b Kinetics of clinical recovery and c percent
survival in anti-TNF treated GFAPΔR1γ mice relative to control treated GFAPΔR1γ and WT mice. Data represent the mean values and ± SEM of four
separate experiments with five mice per group per experiment. P values are determined by Student’s t test. d Percentage area of demyelination
in spinal cord white matter calculated by analysis of transverse sections at six separate levels per mouse. Data represent the mean ± SEM of seven
to nine individual mice per group. Statistical differences determined by two-tailed unpaired t test with *p < 0.05
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specific effect on macrophages. Effector T cells are
primary mediators of disability during EAE [43–45] and
both Th1 and Th17 cells are increased in the CNS of
GFAPγR1Δ mice during disease progression relative to
WT mice [24, 25]. To determine whether TNF block-
ade preferentially reduced a specific subset, thereby
altering the ratio of Th1 and Th17 cells, we assessed
the number of CD4+ T cells producing IFN-γ or IL-17,
respectively. Anti-TNF treatment reduced both effector
Th1 and Th17 cells to a similar extent approximating
the numbers in WT mice (Fig. 4c). These data are consist-
ent with an unbiased reduction in CNS inflammatory
cells, confirming TNF as a critical pro-inflammatory cyto-
kine promoting the maintenance of effector T cells within
the CNS.
Uncontrolled CNS inflammatory responses may be
driven by ongoing peripheral immune activation [46–49].
We therefore examined the effect of TNF blockade on
peripheral effector T cell responses in GFAPγR1Δ mice by
measuring MOG35-55-specific cytokine secretion. Splenic
T cells from GFAPγR1Δ mice with progressive EAE
secreted increased IFN-γ and IL-17 compared to WT with
EAE. Importantly however, anti-TNF treatment did not
reduce the levels of either T cell-produced cytokine in
splenic T cells (Fig. 4d). Similar results were obtained
following analysis of T cells derived from cervical lymph
nodes (data not shown).
TNF affects blood brain barrier integrity
Among its many pleiotropic functions, TNF increases
BBB permeability by disrupting tight junctions [46–49].
The finding that TNF blockade did not reduce periph-
eral self-reactive effector T cells suggested that TNF
influenced CNS inflammation via altering BBB integ-
rity. Both brains and spinal cords of GFAPγR1Δ with
progressive EAE exhibited increased BBB permeability
compared to WT mice with resolving EAE (Fig. 5a).
Anti-TNF treatment restored BBB integrity in GFAPγR1Δ
to that exhibited by WT mice. Restoration of BBB in-
tegrity by TNF blockade in the spinal cord was con-
firmed by immunohistochemistry (Fig. 5b). Staining for
laminin, IgG, and nuclei in spinal cords from WT mice
with resolving EAE showed most serum IgG contained
within blood vessels, whereas serum IgG had clearly
leaked into the parenchyma in GFAPγR1Δ mice. Spinal
cords from GFAPγR1Δ treated with anti-TNF exhibited
reduced serum IgG leakage into the spinal cord paren-
chyma. These data support the concept that ongoing
Fig. 4 Anti-TNF treatment decreases inflammation during progressive EAE. a Total numbers of CD45hi inflammatory cells in the CNS at d30 p.i. of
WT and GFAPγR1Δ mice treated with α-TNF or α-βgal mAb. b Frequencies of CD8+ and CD4+ T cells as well as CD11b+ myeloid cells within
CD45hi infiltrating cells in the CNS of the three mouse groups as depicted. c Total numbers of Th1 (IFN-γ-producing) and Th17 (IL-17 producing)
CD4+ T cells derived from the CNS (d30 p.i.) assessed after PMA and ionomycin stimulation. d IFN-γ and IL-17 in supernatants of splenocytes
from immunized mice (d30 p.i.) stimulated with MOG35–55 peptide as determined by ELISA. Data represent the mean values and ± SEM of three
separate experiments with five mice per group per experiment. P values determined by Student’s t test
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BBB disruption contributes to progressive EAE and that
one aspect of protection by TNF blockade is restoration
of BBB integrity.
TNF blockade promotes anti-inflammatory responses
TNF-induced activation of macrophages and microglia
in vitro and in vivo [36, 50–53] is also a hallmark of
progressive EAE in GFAPγR1Δ mice [24, 25]. MHC
class II expression was evaluated as an activation
marker to verify that TNF blockade reduces macro-
phage and microglial activation. Elevated MHC class II
expression on macrophages and to a lesser extent on
microglia within the CNS of GFAPγR1Δ compared to
WT mice [24, 25] was indeed counteracted by anti-
TNF treatment (Fig. 6a). Reduced MHC class II expres-
sion on both the infiltrating macrophages and microglia
implied reduced activation and antigen presenting cap-
acity of macrophages, thereby further limiting sustained
inflammation.
The promotion of anti-inflammatory factors, particu-
larly IL-10, may provide an additional mechanism by
which TNF blockade diminishes effector T cell function.
This notion is consistent with decreased IL-10, an
inflammatory regulator limiting MHC class II expression
on antigen presenting cells [54, 55], in the CNS of
GFAPγR1Δ mice with progressive EAE. TNF blockade
did elevate IL-10 within the CNS. Although the rwofold
increase was significant, it did not reach levels found
in WT mice undergoing disease remission (Fig. 6b).
Primary sources of IL-10 during EAE include Foxp3+
T regulatory cells (Treg) and the IL-27-dependent
antigen specific T regulatory (Tr-1) cells [56–59]. As
overall numbers of CD4+ T cells, including Th1 and
Th17 cells were reduced by anti-TNF treatment, increased
IL-10 suggested a more prominent function of either
regulatory cell type. Both Foxp3 mRNA levels (Fig. 6c)
as well as Foxp3+ CD4+ T cells (data not shown) were
similar in anti-TNF treated GFAPγR1Δ mice and controls,
confirming a relative increase compared to pathogenic
effector T cells. Transcript levels for IL-27p28, required to
promote Tr-1 cells, was even increased ~3-fold (Fig. 6d),
suggesting that TNF may contribute to progressive disease
via suppressing Tr-1 cells in addition to sustaining MHC
class II expression.
Discussion
Despite preclinical data strongly supporting beneficial
effects of suppressing TNF, TNF blockade in MS pa-
tients has shown variable success. For example, treating
relapsing-remitting patients with a soluble TNFR1 fusion
protein that neutralizes TNF increased the relapse rate
and neurological deficits [15]. Similarly, increased lesion
numbers and lymphocytes following anti-TNF mAb
treatment in two patients with rapidly progressing MS
was consistent with disease exacerbation [14]. By con-
trast, treatment of progressive MS patients with the TNF
inhibiting drug pirfenidone reduced the incidence of
relapses [31, 32]. The ineffectiveness of anti-TNF im-
mune therapy in acute and progressive MS likely reflects
the divergent roles of downstream signaling via the two
TNF receptors as well as the clinical state or phase dur-
ing treatment. This concept is supported by dampened
Fig. 5 TNF blockade restores BBB integrity during progressive EAE. a BBB integrity in brains and spinal cords determined by sodium fluorescein
permeability assay determined at day 25 p.i. in WT and GFAPγR1Δ mice treated with α-TNF or control mAb. Data is represented as fold increase
over naïve values with six mice per group. b Confocal images (Z-stack, magnification ×40) of spinal cords stained with laminin (green), IgG (red),
and DAPI (blue) at d30 p.i. Images representative of two individual mice per group. P values determined by Student’s t test
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disease severity following TNF blockade during the early
acute phase of EAE, when TNF primarily exerts effects
through TNFR1. By contrast, as the local inflammatory
response including TNF expression evolves, thereby in-
ducing TNFR2 expression, TNF blockade also abrogates
protective TNFR2 signaling events that both induce
remyelination and immunosuppressive action [18, 19].
Although the induction of nerve growth factor (NGF),
which can suppress TNF/TNFR1 signaling, has been
implicated in anti-inflammatory effects of TNF/TNFR2
signaling in promoting remyelination [60–62], analysis
of NGF mRNA induction in spinal cords did not reveal
significant differences following anti-TNF treatment in
mice undergoing progressive EAE (data not shown).
NGF mRNA levels were increased ~6-fold in both
treated and control treated groups relative to naïve mice
at day 30 p.i. Furthermore, analysis of mRNA expression
for brain-derived neurotropic factor (BDNF), also impli-
cated in promoting remyelination [4, 60, 63], revealed
no induction at day 30 post EAE induction in spinal
cords of GFAPγR1Δ mice treated or not with anti-TNF
Ab relative naïve mice (data not shown). Our data thus
demonstrate that TNF blockade during a sustained acute
disease, as reflected in the pathogenesis of progressive
MS, results in a diminution of both clinical disability
and lesion progression independent of NGF or BDNF
mRNA alterations.
Activation-induced production of TNF by numerous
cell types further contributes to the complex regulation
of TNF and distinct outcomes of intervention. Both
microglia/macrophages and astrocytes can secrete TNF
in vitro and in vivo, yet little is known on the regulation
in vivo [40, 41]. In MS, TNF is associated with both
astrocytes and foamy macrophages at the edge and cen-
ter of the lesion, respectively [2]. In vitro stimulation of
astrocytes with lipopolysaccharide and IFN-γ induces
TNF production, whereas IFN-γ stimulation alone does
not [41]. However, astrocytes purified from dual trans-
genic GFAPγR1Δ/GFAP-GFP reporter mice during pro-
gressive EAE expressed minimal TNF mRNA. This was
confirmed by the inability to detect TNF production by
astrocytes in vivo either in WT mice during acute and
post-acute EAE or in mice exhibiting progressive EAE.
There was also no evidence for T cell-mediated TNF
production in vivo. Our data rather confirmed that TNF
is primarily produced by both infiltrating macrophages
and microglia during acute MOG induced EAE [37].
Similarly, GFAPΔR1γ mice displayed no alterations in
the cellular TNF pattern during acute disease, although
TNF+ cells were slightly increased (Fig. 1). Surprisingly,
while TNF production was considerably reduced by both
macrophages and microglia during the recovery phase in
WT mice, TNF production was specifically sustained in
CNS infiltrating macrophages, but not microglia, during
progressive EAE. Together, our results suggest that the
sustained clinical disease, disability, increased mortality,
and increasing tissue damage associated with progressive
disease are all associated with TNF production by the
Fig. 6 TNF neutralization promotes anti-inflammatory responses. a MHC class II expression on macrophages and microglia derived from WT
and GFAPγR1Δ mice treated with α-TNF or control mAb determined by flow cytometry at d30p.i. b IL-10 levels in the CNS of mouse groups as
depicted determined by ELISA (D30p.i.). Foxp3 (c) and IL-27p28 (d) mRNA expression in the CNS determined by RT-PCR. Data represent the mean
values and ± SEM of three separate experiments with five mice per group per experiment. P values determined by Student’s t test
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infiltrating macrophage population and not microglia.
These are the first data demonstrating differential
regulation of TNF expression in macrophages versus
microglia in an environment of sustained inflammation
established by the inability of astrocytes to respond to
IFN-γ. While these results support an astrocyte dependent
component in specifically affecting ongoing TNF expres-
sion by bone marrow derived macrophages, the under-
lying molecular mechanisms remain to be resolved. A
better understanding of the relative expression of soluble
versus membrane bound TNF as well as the balance
between TNFR1 versus TNFR2 engagement on distinct
CNS cell types may provide clues. We can also not
exclude dysregulation of the TNF, NGF, and BDNF signal-
ing triad in contributing to progressive disease [60], as
signaling not only of TNF but also neurotropic factors
may be altered.
The protective effect of anti-TNF Ab treatment on
progressive EAE supported that macrophage-derived
TNF is a detrimental contributor to disability. Improved
clinical disease and survival directly coincided with di-
minished cellular CNS inflammation and demyelination.
Interestingly, TNF blockade decreased the overall num-
bers of CNS infiltrating immune cells, without affecting
a specific population or the ratio of Th1 and Th17 cells.
A potential therapeutic mechanism by which TNF block-
ade reduces CNS inflammation during progressive EAE
is the regulation of peripheral immune response, similar
to the effects described during induction of acute EAE
[64]. However, TNF blockade did not reduce increased
self-reactive Th1 and Th17 responses in the periphery,
suggesting that the primary site of detrimental TNF
activity is within the CNS. A critical anatomical site
affected by TNF is the BBB, which is not only is essential
to maintain CNS homeostasis [65] but also limits CNS
access of peripheral inflammatory cells [66]. TNF is
implicated in disruption of the BBB in several models of
CNS inflammation [46–49, 67, 68]. In EAE, TNF dis-
rupts the BBB by altering tight junctions [46–49],
thereby promoting the influx of inflammatory cells into
the CNS parenchyma. Moreover, TNF-/- mice have re-
duced BBB permeability compared to WT mice during
EAE [67]. Consistent with these reports, decreased infil-
tration of immune cells by TNF blockade during pro-
gressive EAE correlated with prevention of further BBB
breakdown noted in untreated mice. In this context, it is
interesting to note that TNF activates IL-6 production
and signaling in human primary endothelial cells in vitro,
which synergizes with TNF to promote permeabilization
[69]. IL-6 blockade during progressive EAE also amelio-
rated disease progression, but to a lesser extent than anti-
TNF treatment [25], supporting a more prominent role of
TNF. Whether control of BBB breakdown was the
primary mechanism by which TNF blockade ameliorated
progressive CNS pathology remains unclear. Increased T
cell proliferation in the CNS during progressive EAE [25]
may reflect facilitated recruitment of peripherally activated
cells resuming proliferation in the CNS. Alternatively,
TNF may drive local proliferation independent of increased
BBB permeability.
An additional mechanism associated with the fail-
ure to transition from acute autoimmune mediated-
inflammation towards remission in progressive EAE
is dysregulation of IL-10, a potent regulator of T cell
activation [54, 55, 70]. IL-10, produced primarily by
Treg and Tr1 cells during EAE [71], is decreased during
progressive EAE in GFAPγR1Δ mice [24]. Furthermore,
IL-10-/- mice are susceptible to severe EAE, whereas IL-10
administration suppresses acute disease [57, 71, 72]. TNF
blockade indeed increased IL-10 expression within the
CNS concomitant with upregulation of IL-27 required for
the conversion of antigen specific CD4+ T cells into IL-10
secreting Tr1 cells [57, 58, 73–75]. By contrast, frequen-
cies of Treg within the CNS remained unaltered. Un-
checked TNF may thus counteract establishment of an
anti-inflammatory milieu by limiting IL-27 expression and
suppressing the induction of Tr1 cells. In a viral-induced
demyelination model, IL-10 controls demyelination by
limiting both the size and number of demyelinating
lesions [76]. GFAPγR1Δ mice exhibit increased demyelin-
ation during EAE, which correlates with decreased IL-10
levels [24, 25]. Interestingly, anti-TNF treatment also
significantly reduced demyelination in GFAPγR1Δ mice,
suggesting increased IL-10 may contribute to controlling
demyelination during progressive EAE after anti-TNF
treatment.
TNF has also been implicated in promoting macro-
phage polarization to a pro-inflammatory M1 phenotype
following spinal cord injury, thereby contributing to
tissue damage [36]. Using MHC class II expression as a
readout, TNF blockade decreased macrophage and to a
lesser extent microglia activation. While this supported a
paracrine effect of sustained macrophage production of
TNF on promoting microglial activation, the cause and
effect of simultaneously suppressed IL-10, which also
reduces MHC class II expression [54, 55, 70] remains to
be elucidated. Furthermore, as TNF is initially produced
as transmembrane TNF, neither histological evaluation
nor intracellular flow cytometry can distinguish between
the potential contributions of soluble TNF/TNFR1 ver-
sus transmembrane TNF/TNFR2 interactions to patho-
genesis or disease resolution. Sustained TNF in the
absence of IFN-γ signaling to astrocytes may alter the
status of protective TNFR2 expression on glia or infil-
trating macrophages. In WT mice undergoing EAE,
clinical conversion to remission may be associated with
preferential TNFR2 expression and/or membrane bound
TNF. This pathway may be dysregulated in progressive
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EAE by enhanced proteolytic activity resulting in soluble
TNF.
Conclusions
Our data demonstrate that sustained TNF production
by CNS infiltrating macrophages promotes BBB per-
meability, inflammation, and demyelination, thereby
progressively increasing disability and morbidity. While
our studies confirmed the failure of anti-TNF therapy in
WT mice undergoing EAE [13, 22, 23], blockade of sus-
tained TNF ameliorated both disease severity and limited
ongoing demyelination during progressive EAE. Import-
antly, our results are reminiscent of studies demonstrating
a reduction in relapses and improved disability with only
mild secondary effects in secondary progressive MS pa-
tients treated with the TNF inhibitor pirfenidone [31, 32].
Together, these data support a therapeutic approach to
limiting TNF as a potential treatment to slow down or halt
progressive forms of MS.
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